Abbvie Q3 Adjusted Diluted Earnings Per Share Guidance Range, Including Impact Of Q3 2023 Acquired IPR&D And Milestones Expense, Is $2.76-$2.86 Vs $2.88 Est
Portfolio Pulse from Benzinga Newsdesk
Abbvie has updated its Q3 2023 guidance for adjusted diluted earnings per share (EPS) to a range of $2.76-$2.86, including the impact of acquired IPR&D and milestones expense. This is lower than the estimated $2.88.
October 04, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Abbvie's lower than expected Q3 2023 EPS guidance may negatively impact its stock price in the short term.
Earnings per share (EPS) is a key indicator of a company's profitability. Lower than expected EPS often leads to a decrease in the company's stock price as it indicates that the company may not be performing as well as investors expected. In this case, Abbvie's lower than expected Q3 2023 EPS guidance may lead to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100